公开(公告)号：US20250009742A1

公开(公告)日：2025-01-09

申请号：US18699156

申请日：2022-10-12

Applicant: AM SCIENCES INC ,  KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY

Inventor： Nakcheol JEONG ,  Misun LEE ,  Heewoo SIM ,  Myungjin KIM ,  Jung-Hee KIM ,  Soo Bong HAN ,  Young Sik JUNG ,  Hye jin KIM ,  Chang Soo YUN ,  Heeyeong CHO ,  Mee Hyein KIM ,  Joo Youn LEE

IPC: A61K31/501 ,  A61K31/4155 ,  A61K31/4162 ,  A61K31/422 ,  A61K31/437 ,  A61K31/4439 ,  A61K31/506 ,  A61P31/20 ,  C07D231/12 ,  C07D231/16 ,  C07D231/56 ,  C07D401/12 ,  C07D401/14 ,  C07D403/12 ,  C07D403/14 ,  C07D405/14 ,  C07D471/04 ,  C07D491/052 ,  C07D491/056 ,  C07D495/04

Abstract: The present invention relates to a series of novel pyrazolylmethylurea derivatives, and the use thereof for the inhibition of capsid assembly and the prevention or treatment of viral diseases through the inhibition.

公开(公告)号：US20230365582A1

公开(公告)日：2023-11-16

申请号：US18042352

申请日：2021-08-20

Applicant: KANAPH THERAPEUTICS INC. ,  KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY

Inventor： Young Sook SHIN ,  Sang Kyun LIM ,  Yeri LEE ,  Donggeon KIM ,  Soo Bong HAN ,  Chang Soo YUN ,  Hyun Jin KIM ,  Joo Youn LEE ,  Hyuk LEE ,  Sikwang SEONG

IPC: C07D495/04 ,  C07D333/24 ,  C07D333/38 ,  C07D409/10 ,  C07D409/06

CPC classification number: C07D495/04 ,  C07D333/24 ,  C07D333/38 ,  C07D409/10 ,  C07D409/06

Abstract: The present application relates to a novel compound having inhibitory activity on prostaglandin E2 receptor and uses thereof, and provides a compound represented by formula I, a solvate, stereoisomer or pharmaceutically acceptable salt thereof, a pharmaceutical composition comprising the same, and a method of using the same.

公开(公告)号：US20230248734A1

公开(公告)日：2023-08-10

申请号：US18001333

申请日：2021-06-08

Applicant: KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY

Inventor： Soo Bong HAN ,  Jin Soo SHIN ,  Mee Hyein KIM ,  Eunhye JUNG ,  Ye Jin JANG ,  Hyuk LEE ,  Myoungkyu LEE ,  Dongsu KIM ,  Chang Soo YUN ,  Young Sik JUNG

IPC: A61K31/53 ,  A61K31/495 ,  A61K31/138 ,  A61K31/4402 ,  A61K31/137 ,  A61K31/4164 ,  A61K31/451 ,  A61K31/452 ,  A61K31/4453 ,  A61K31/40 ,  A61K31/445 ,  A61P31/14 ,  G01N33/50

CPC classification number: A61K31/53 ,  A61K31/495 ,  A61K31/138 ,  A61K31/4402 ,  A61K31/137 ,  A61K31/4164 ,  A61K31/451 ,  A61K31/452 ,  A61K31/4453 ,  A61K31/40 ,  A61K31/445 ,  A61P31/14 ,  G01N33/5091

Abstract: The present invention relates to the development of a composition for the treatment of novel SARS-coronavirus-2 infection. The drug efficacy was evaluated through CPE (Cytopathic Effect)-based assay method that measures how long the cells survive by infecting SARS-CoV-2 after receiving a drug library previously approved as a treatment for a specific disease from the Korea Chemical Bank and treating Vero cells with the drug, and an image-based assay that measures how much virus is reduced in infected cells. Through this, 16 kinds of drugs effective in the treatment of SARS-CoV-2 were re-positioned.

公开(公告)号：US20170145007A1

公开(公告)日：2017-05-25

申请号：US15319151

申请日：2015-05-21

Applicant: KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY

Inventor： Chang Soo YUN ,  Hyoung Rae KIM ,  Sung Yun CHO ,  Hee Jung JUNG ,  Kwangho LEE ,  Chong Hak CHAE ,  Chong Ock LEE ,  Chi Hoon PARK ,  Pilho KIM ,  Jong Yeon HWANG ,  Jae DU HA ,  Sun Joo AHN

IPC: C07D471/04 ,  C07D405/14 ,  C07D401/14 ,  C07D403/12 ,  C07D401/12

CPC classification number: C07D471/04 ,  A61K31/506 ,  C07D209/04 ,  C07D239/12 ,  C07D401/12 ,  C07D401/14 ,  C07D403/12 ,  C07D405/14

Abstract: The present invention relates to a pyrimidine-2,4-diamine derivative or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition for prevention or treatment of cancer comprising the same as an effective ingredient. A compound according to the present invention has the good effect of inhibiting anaplastic lymphoma kinase (ALK) activity, whereby a therapeutic effect on cancer cells having an anaplastic lymphoma kinase (ALK) fusion protein such as EML4-ALK, NPM-ALK, etc. can be enhanced and it is expected that a recurrence of cancer will be effectively inhibited. As such, the compound can be effectively used in a pharmaceutical composition for prevention or treatment of cancer.

公开(公告)号：US20200062730A1

公开(公告)日：2020-02-27

申请号：US16609805

申请日：2018-05-11

Applicant: KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY

Inventor： Jong Yeon HWANG ,  Jae Du HA ,  Sung Yun CHO ,  Pil Ho KIM ,  Chang Soo YUN ,  Chi Hoon PARK ,  Chong Ock LEE ,  Sang Un CHOI ,  Joo Youn LEE ,  Sunjoo AHN

IPC: C07D401/04 ,  A61P35/00 ,  C07D401/14

Abstract: The present disclosure relates to a novel piperidine-2,6-dione derivative and a use thereof and, more specifically, to a piperidine-2,6-dione derivative compound having a structure of a thalidomide analog. A compound of chemical formula 1 according to the present disclosure specifically binds with CRBN protein, and is involved in functions thereof. Therefore, the compound of the present disclosure can be favorably used in the prevention or treatment of leprosy, chronic graft versus host disease, an inflammatory disease, or cancer, which are caused by actions of CRBN protein.

公开(公告)号：US20250161271A1

公开(公告)日：2025-05-22

申请号：US18838591

申请日：2023-02-15

Applicant: KANAPH THERAPEUTICS INC. ,  KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY

Inventor： Donggeon KIM ,  Yeri LEE ,  Sang Kyun LIM ,  Young Sook SHIN ,  Soo Bong HAN ,  Chang Soo YUN ,  Hyuk LEE ,  Hyun Jin KIM ,  Joo Youn LEE ,  Si Kwang SEONG ,  Taeyoung YOON ,  Youngrae LEE

IPC: A61K31/407 ,  A61K31/381 ,  A61K31/397 ,  A61K31/4155 ,  A61K31/4436 ,  A61K31/4535 ,  A61K31/496 ,  A61K31/506 ,  A61K31/5377 ,  A61K45/06 ,  A61P35/00

Abstract: The present invention provides a pharmaceutical composition for treating cancer, comprising a novel compound that inhibits the activity of prostaglandin E2 receptor and an anticancer agent as active ingredients. The novel compound of the present invention inhibited the activity of prostaglandin E2 receptor and inhibited tumor growth in colorectal cancer and lung cancer tumor models. In addition, it was found that when administered in combination with other anticancer agents such as a chemotherapeutic agent and/or an immune checkpoint inhibitor, a synergistic effect was exhibited in anticancer activity. Therefore, a pharmaceutical composition for treating cancer, comprising the novel compound and an anticancer agent as active ingredients may be effectively used for the prevention and treatment of cancer.

公开(公告)号：US20240252488A1

公开(公告)日：2024-08-01

申请号：US18246773

申请日：2021-09-27

Applicant: KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY ,  HUONS CO., LTD.

Inventor： Jong Yeon HWANG ,  Hyunjun KIM ,  Hyowon MUN ,  Hyun Jin KIM ,  Jae Du HA ,  Sung Yun CHO ,  Chang Soo YUN ,  Pilho KIM ,  Jisoo LEE ,  Joon Gyo OH

IPC: A61K31/497 ,  A61K31/4439 ,  A61K31/444 ,  A61K47/54 ,  A61K47/55 ,  C07D401/04 ,  C07D401/14 ,  C07D403/04 ,  C07D403/14

CPC classification number: A61K31/497 ,  A61K31/4439 ,  A61K31/444 ,  A61K47/545 ,  A61K47/55 ,  C07D401/04 ,  C07D401/14 ,  C07D403/04 ,  C07D403/14

Abstract: The present disclosure provides a compound of a specific chemical structure binding to MLKL or having an MLKL inhibiting or degrading activity, or pharmaceutically acceptable salts thereof. The present disclosure provides a composition comprising such compound or pharmaceutically acceptable salts thereof. The present disclosure provides the pharmaceutical use of the compound according to the present invention, salts thereof, and a composition comprising same for treating or preventing MLKL-related diseases. The present disclosure also provides a method for treating or preventing MLKL-related diseases, comprising administering to a subject in need of treatment an effective amount of a compound according to the present invention, salts thereof, or a composition comprising same.

公开(公告)号：US20220105188A1

公开(公告)日：2022-04-07

申请号：US17429321

申请日：2020-02-07

Applicant: KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY ,  KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY

Inventor： Jong Yeon HWANG ,  Jae Du HA ,  Sung Yun CHO ,  Pilho KIM ,  Chang Soo YUN ,  Hyun Jin KIM ,  Sung Goo PARK ,  Byoung Chul PARK ,  Jeong Hoon KIM ,  Sunhong KIM

IPC: A61K47/55 ,  A61K47/54

Abstract: The present invention relates to a target protein degradation-inducing Degraducer, a preparation method thereof, and a pharmaceutical composition for preventing or treating diseases related to EED, EZH2, or PRC2 comprising same as an active ingredient. A novel compound represented by formula 1, according to the present invention is a Degraducer compound that induces degradation of a target protein, i.e., EED or PRC2, utilizing cereblon E3 ubiquitin ligase, VHL E3 ubiquitin ligase, MDM2 E3 ubiquitin ligase, and cIAP E3 ubiquitin ligase, wherein the compound has an aspect of remarkably achieving target protein degradation-inducing activity through a ubiquitin proteasome system (UPS), and therefore there is a useful effect in that it is possible to provide a pharmaceutical composition for preventing or treating diseases or conditions related to a target protein, and a functional health food composition for preventing or improving same, comprising said compound as an active ingredient.

公开(公告)号：US20180104242A1

公开(公告)日：2018-04-19

申请号：US15567224

申请日：2015-12-30

Applicant: KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY

Inventor： Jong Yeon HWANG ,  Hyoung Rae KIM ,  Jae Du HA ,  Sung Yun CHO ,  Hee Jung JUNG ,  Pilho KIM ,  Chang Soo YUN ,  Chong Ock LEE ,  Chi Hoon PARK ,  Chong Hak CHAE ,  Sunjoo AHN

IPC: A61K31/506 ,  A61P35/00 ,  C07D239/48 ,  C07D239/30 ,  C07C13/48 ,  C07B43/04

CPC classification number: A61K31/506 ,  A23L33/10 ,  A61P35/00 ,  C07B43/04 ,  C07B2200/07 ,  C07C13/48 ,  C07D239/30 ,  C07D239/48

Abstract: The present invention relates to a 4-(2-amino-tetrahydronaphthaleneyl)pyrimidine derivative, a preparation method thereof, and a pharmaceutical composition for the prevention or treatment of cancer comprising the same as an active ingredient. The 4-(2-amino-tetrahydronaphthaleneyl)pyrimidine derivative, the optical isomer thereof, or the pharmaceutically acceptable salt thereof of the present invention is very effective in suppressing anaplastic lymphoma kinase (ALK) activity and as a result it can improve the effectiveness of treatment on cancer cells having anaplastic lymphoma kinase (ALK) fusion proteins such as EML4-ALK and NPM-ALK, so that it can be effectively used as a pharmaceutical composition for preventing or treating cancer.

公开(公告)号：US20140249162A1

公开(公告)日：2014-09-04

申请号：US14278955

申请日：2014-05-15

Applicant: KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY

Inventor： Jong Chan SON ,  Bong Jin KIM ,  Jae Hak KIM ,  Ill Young LEE ,  Chang Soo YUN ,  Sang Ho LEE ,  Chong Kgo LEE

IPC: C07D471/04

CPC classification number: C07D471/04

Abstract: The present invention relates to a pyrrolopyridine derivative represented by the Chemical Formula I, and a racemate or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, and relates to an antiviral composition including the same as an active ingredient. The compound of the Chemical Formula I has excellent antiviral activity and selectivity for wild type and resistant HIV-1, and thereby is useful as a therapeutic agent for acquired immune deficiency syndrome (AIDS).

Abstract translation: 本发明涉及由化学式I表示的吡咯并吡啶衍生物及其外消旋物或其立体异构体或其药学上可接受的盐，涉及包含其作为活性成分的抗病毒组合物。 化学式I的化合物对野生型和抗性HIV-1具有优异的抗病毒活性和选择性，因此可用作获得性免疫缺陷综合征（AIDS）的治疗剂。